NEW YORK – NeoGene, a developer of personalized neoantigen T-cell therapies, announced Monday that it has raised $110 million in Series A financing.
The financing was led by Jeito Capital and new investors including EcoR1 Capital and Syncona, in addition to support from seed investors Vida Ventures, TPG, and Two River.